FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054177711> ?p ?o ?g. }

• W2054177711 endingPage "574" @default.
• W2054177711 startingPage "561" @default.
• W2054177711 abstract "KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs. From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS wild-type cell lines (SW48 and CaCo2). In vitro, using poly-D-lysine/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS wild-type lines showed sensitivity to cetuximab. Treatment with cetuximab and dasatinib showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo. To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, dasatinib or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells. The results of this experiment showed a decrease in a broad spectrum of kinases centered on the β-catenin pathway, the mitogen-activated protein kinase (MAPK) pathway, AKT/mammalian target of rapamycin (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments. Next, we analyzed tumor growth with cetuximab, dasatinib or their combination in vivo. KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS wild type demonstrated an antitumor response when treated with cetuximab. KRAS mutant tumors exhibited minimal response to dasatinib monotherapy. However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and dasatinib. Combinatorial treatment of KRAS mutant xenografts resulted in decreased cell proliferation, as measured by Ki67, and higher rates of apoptosis, as measured by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). The data presented in this study indicate that dasatinib can sensitize KRAS mutant CRC tumors to cetuximab and may do so by altering the activity of several key signaling pathways. Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for clinical trials combining cetuximab and dasatinib in the KRAS mutant CRC genetic setting." @default.
• W2054177711 created "2016-06-24" @default.
• W2054177711 creator A5022135015 @default.
• W2054177711 creator A5023671134 @default.
• W2054177711 creator A5039868720 @default.
• W2054177711 creator A5039980388 @default.
• W2054177711 creator A5073377082 @default.
• W2054177711 creator A5076369520 @default.
• W2054177711 creator A5081927868 @default.
• W2054177711 creator A5089257042 @default.
• W2054177711 date "2010-10-18" @default.
• W2054177711 modified "2023-09-28" @default.
• W2054177711 title "Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab" @default.
• W2054177711 cites W145415622 @default.
• W2054177711 cites W1532635242 @default.
• W2054177711 cites W1589166971 @default.
• W2054177711 cites W1594706458 @default.
• W2054177711 cites W1639582946 @default.
• W2054177711 cites W1796290743 @default.
• W2054177711 cites W1854123316 @default.
• W2054177711 cites W1963570775 @default.
• W2054177711 cites W1964321121 @default.
• W2054177711 cites W1965095341 @default.
• W2054177711 cites W1970213932 @default.
• W2054177711 cites W1975972551 @default.
• W2054177711 cites W1976197008 @default.
• W2054177711 cites W1977267072 @default.
• W2054177711 cites W1979971719 @default.
• W2054177711 cites W1996275566 @default.
• W2054177711 cites W1999250974 @default.
• W2054177711 cites W2001258296 @default.
• W2054177711 cites W2004439203 @default.
• W2054177711 cites W2004900348 @default.
• W2054177711 cites W2007121859 @default.
• W2054177711 cites W2022051845 @default.
• W2054177711 cites W2022847745 @default.
• W2054177711 cites W2028974992 @default.
• W2054177711 cites W2030565228 @default.
• W2054177711 cites W2032674547 @default.
• W2054177711 cites W2034862875 @default.
• W2054177711 cites W2037297522 @default.
• W2054177711 cites W2038624343 @default.
• W2054177711 cites W2038900319 @default.
• W2054177711 cites W2042327295 @default.
• W2054177711 cites W2042604521 @default.
• W2054177711 cites W2042746242 @default.
• W2054177711 cites W2042794591 @default.
• W2054177711 cites W2043103956 @default.
• W2054177711 cites W2046163031 @default.
• W2054177711 cites W2052371969 @default.
• W2054177711 cites W2057623977 @default.
• W2054177711 cites W2063160236 @default.
• W2054177711 cites W2065429233 @default.
• W2054177711 cites W2066671615 @default.
• W2054177711 cites W2069800089 @default.
• W2054177711 cites W2074473619 @default.
• W2054177711 cites W2075954169 @default.
• W2054177711 cites W2076370383 @default.
• W2054177711 cites W2076718022 @default.
• W2054177711 cites W2079948123 @default.
• W2054177711 cites W2098223440 @default.
• W2054177711 cites W2100712519 @default.
• W2054177711 cites W2113615565 @default.
• W2054177711 cites W2120492882 @default.
• W2054177711 cites W2121881330 @default.
• W2054177711 cites W2131361386 @default.
• W2054177711 cites W2134850272 @default.
• W2054177711 cites W2153516980 @default.
• W2054177711 cites W2155311724 @default.
• W2054177711 cites W2156480395 @default.
• W2054177711 cites W2157769714 @default.
• W2054177711 cites W2158475201 @default.
• W2054177711 cites W2163046152 @default.
• W2054177711 cites W2164837623 @default.
• W2054177711 cites W2165132869 @default.
• W2054177711 cites W2167241562 @default.
• W2054177711 cites W2167539263 @default.
• W2054177711 cites W2168213749 @default.
• W2054177711 cites W2171596565 @default.
• W2054177711 cites W2310034942 @default.
• W2054177711 cites W2332502334 @default.
• W2054177711 cites W4211075026 @default.
• W2054177711 cites W4247947439 @default.
• W2054177711 cites W4249092084 @default.
• W2054177711 cites W4253357698 @default.
• W2054177711 cites W45936251 @default.
• W2054177711 doi "https://doi.org/10.1038/onc.2010.430" @default.
• W2054177711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3025039" @default.
• W2054177711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20956938" @default.
• W2054177711 hasPublicationYear "2010" @default.
• W2054177711 type Work @default.
• W2054177711 sameAs 2054177711 @default.
• W2054177711 citedByCount "112" @default.
• W2054177711 countsByYear W20541777112012 @default.
• W2054177711 countsByYear W20541777112013 @default.
• W2054177711 countsByYear W20541777112014 @default.
• W2054177711 countsByYear W20541777112015 @default.
• W2054177711 countsByYear W20541777112016 @default.

• next